<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138904</url>
  </required_header>
  <id_info>
    <org_study_id>DAUH-AGC-10-1</org_study_id>
    <nct_id>NCT01138904</nct_id>
  </id_info>
  <brief_title>FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)</brief_title>
  <official_title>Randomized Phase II Study of FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Patients With Advanced or Relapsed Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dong-A University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FOLFOX* followed by FOLFIRI** or reverse sequence treatment regimen have been used as a&#xD;
      standard treatment modality in metastatic colorectal cancer.Oxaliplatin and Irinotecan were&#xD;
      used for advanced gastric cancer also. The investigators study was designed to evaluate the&#xD;
      safety and efficacy of FOLFOX followed by FOLFIRI or reverse sequence treatment regimen as a&#xD;
      first-line and second line therapy for patients with relapsed or metastatic gastric cancer&#xD;
      similar with colorectal cancer.&#xD;
&#xD;
      *FOLFOX: oxaliplatin followed by leucovorin before bolus 5-FU followed by continuous infusion&#xD;
      5-FU&#xD;
&#xD;
      **FOLFIRI: irinotecan followed by leucovorin before bolus 5-FU followed by continuous&#xD;
      infusion 5-FU&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer remains a major public health issue, and is the fourth most common cancer and&#xD;
      the second leading cause of cancer deaths worldwide. In Korea, gastric cancer is the most&#xD;
      common cancer in men, the second most common cancer in women, and the second leading cause of&#xD;
      cancer death. Despite the development of early gastric cancer detection programs, more than&#xD;
      two-thirds of patients diagnosed with gastric cancer will develop unresectable disease. Even&#xD;
      patients with operable tumors evidence high rates of both local and distant recurrence. In&#xD;
      cases of advanced gastric cancer, the median survival rate is 9 to 10 months. Additionally,&#xD;
      the overall 5-year survival rate is less than 25% in Korea and Japan.&#xD;
&#xD;
      Several combination regimens of chemotherapy for gastric cancer have been developed, but the&#xD;
      survival advantage appears to be marginal, and no worldwide standard regimens have yet been&#xD;
      established. Recently, a meta-analysis has been conducted to evaluate the efficacy and&#xD;
      tolerability of chemotherapy in patients with advanced gastric cancer. The analysis of&#xD;
      chemotherapy versus best supportive care (Hazard Ratio/HR = 0.39, confidence interval (CI)&#xD;
      95% 0.28-0.52) and combination versus single agent, mainly 5-Fluorouracil (5-FU), (HR = 0.83,&#xD;
      95% CI 0.74-0.93) demonstrated significant OS results in favour of chemotherapy and&#xD;
      combination chemotherapy. Several chemotherapeutic drugs, including 5-fluorouracil (5-FU),&#xD;
      mitomycin C, nitrosoureas, and doxorubicin have evidenced some level of efficacy against&#xD;
      advanced gastric cancer. However, the majority of combination chemotherapy regimens for&#xD;
      advanced gastric cancer have evidenced overall response rates in a range of 30 to 50% in&#xD;
      phase II studies. Furthermore, no new regimens including the use of taxanes or irinotecan&#xD;
      have improved either response or survivals in phase II or III trials other than docetaxel,&#xD;
      cisplatina and infusional 5-FU (DCF) combination.&#xD;
&#xD;
      Oxaliplatin, a third-generation platinum analogue, is a diaminocyclohexane platinum which&#xD;
      forms interstrand DNA adducts, which differ from those formed by cisplatin or carboplatin in&#xD;
      terms of their capability to overcome resistance mechanisms. FOLFOX-4 or FOLFOX-6 combination&#xD;
      regimen have demonstrated response rate of 38%-50% as a first-line treatment of gastric&#xD;
      cancer.&#xD;
&#xD;
      Irinotecan (CPT-11,7-ethyl-10-[4-(1-piperidino)-1-piperidino] is a semi-synthetic plant&#xD;
      alkaloid obtained from Camptotheca acuminate of the Nyssaceae family. After conversion to its&#xD;
      active metabolite, SN-38, irinotecan acts by inhibiting the eukaryotic enzyme,&#xD;
      DNA-topoisomerase I. Single-agent irinotecan has evidenced response rates of 13-23% in cases&#xD;
      of advanced gastric cancer. 5-Fluorouracil (5-FU) and Topoisomerase I inhibitor-based&#xD;
      regimens have demonstrated a response rate of 20-29%, and have been suggested as a first-line&#xD;
      treatment for advanced gastric cancer.&#xD;
&#xD;
      FOLFOX followed by FOLFIRI or reverse sequence treatment regimen have been used as a standard&#xD;
      treatment modality in metastatic colorectal cancer.&#xD;
&#xD;
      The study was designed to evaluate the safety and efficacy of FOLFOX followed by FOLFIRI or&#xD;
      reverse sequence treatment regimen as a first-line and second line therapy for patients with&#xD;
      relapsed or metastatic gastric cancer similar with colorectal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate by RECIST</measure>
    <time_frame>6 month after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year after start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years after start</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>IROX arm: FOLFIRI -&gt; FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IROX arm: FOLFIRI -&gt; FOLFOX&#xD;
FOLFOX REGIMEN&#xD;
D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr&#xD;
Every 2 weeks&#xD;
FOLFILI REGIMEN&#xD;
D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXIR arm: FOLFIRI -&gt; FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OXIR arm: FOLFIRI -&gt; FOLFOX&#xD;
FOLFOX REGIMEN&#xD;
D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr&#xD;
Every 2 weeks&#xD;
FOLFILI REGIMEN&#xD;
D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan, oxaliplatin</intervention_name>
    <description>OXIR: FOLFOX -&gt; FOLFIRI&#xD;
IROX: FOLFIRI -&gt; FOLFOX&#xD;
FOLFOX REGIMEN&#xD;
D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr&#xD;
Every 2 weeks&#xD;
FOLFILI REGIMEN&#xD;
D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr&#xD;
Every 2 weeks</description>
    <arm_group_label>IROX arm: FOLFIRI -&gt; FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin, irinotecan</intervention_name>
    <description>FOLFOX REGIMEN&#xD;
D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr&#xD;
Every 2 weeks&#xD;
FOLFILI REGIMEN&#xD;
D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr&#xD;
Every 2 weeks</description>
    <arm_group_label>OXIR arm: FOLFIRI -&gt; FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed gastric cancer&#xD;
&#xD;
          -  No prior chemotherapy for palliative setting&#xD;
&#xD;
          -  ECOG PS &lt;3&#xD;
&#xD;
          -  Measurable lesion on CT&#xD;
&#xD;
          -  adequate kidney function (CCr ≥ 40 ml/min)&#xD;
&#xD;
          -  adequate liver function (Transaminase &lt; 3 X upper normal value, Bilirubin &lt; 2 mg%)&#xD;
&#xD;
          -  adequate BM function (ANC &gt; 1500/ul, platelet &gt; 75000/ul)&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other cancer history&#xD;
&#xD;
          -  pregnant or breast feeding&#xD;
&#xD;
          -  inadequate general condition for chemotherapy&#xD;
&#xD;
          -  allergy to oxaliplatin or irinotecan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HYUK-CHAN KWON, M.D.,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sung Yong Oh</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2010</study_first_posted>
  <last_update_submitted>November 2, 2014</last_update_submitted>
  <last_update_submitted_qc>November 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University Hospital</investigator_affiliation>
    <investigator_full_name>Sung Yong Oh</investigator_full_name>
    <investigator_title>Department of internal medicine</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>irinotecan</keyword>
  <keyword>sequential treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

